<DOC>
	<DOCNO>NCT00004754</DOCNO>
	<brief_summary>OBJECTIVES : I . Provide epoprostenol ( Flolan , prostaglandin I2 ) chronic infusion patient severe primary pulmonary hypertension alternative therapy available . II . Obtain additional safety information continuous infusion epoprostenol . III . Obtain additional information economic resource health consumption .</brief_summary>
	<brief_title>Phase IV Study Chronic Infusional Epoprostenol Severe Primary Pulmonary Hypertension</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients treat chronic continuous infusion epoprostenol . The high tolerated infusion rate determine patient gradually increase rate target dose reach patient experience least 1 dose-limiting effect . Patients subsequently treat chronic continuous infusion , begin rate high tolerate rate . Attempts make increase dose high tolerated rate first 72 hour .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Severe primary pulmonary hypertension Able prepare selfadminister medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>hypertensive disorder</keyword>
	<keyword>primary pulmonary hypertension</keyword>
	<keyword>rare disease</keyword>
</DOC>